In a groundbreaking development for pediatric oncology, Oncoheroes Biosciences, Inc. has received the FDA's greenlight to proceed with two crucial clinical trials. This milestone opens the door to exploring potential drug treatments for young cancer patients, offering newfound hope in the fight against childhood cancer.
The U.S. Food and Drug Administration (FDA) recently granted Oncoheroes the green light for two Investigational New Drug (IND) applications submitted in August. These applications sought permission to initiate clinical trials for two compounds in Oncoheroes' portfolio: volasertib and dovitinib. Following a meticulous review, the FDA's approval paves the way for innovative treatment options targeting pediatric cancer.
Volasertib: Volasertib operates as an inhibitor of Polo-like-kinase 1 (PLK1), an enzyme with a known role in various cancer progressions. Oncoheroes acquired this compound from Boehringer Ingelheim, which initially developed it for Acute Myeloid Leukemia. Preclinical data highlights its potential for treating rhabdomyosarcoma and other pediatric cancer indications.
Dovitinib: Dovitinib is a pan-tyrosine kinase inhibitor that targets fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), and other receptor tyrosine kinases (RTKs). Oncoheroes exclusively licensed dovitinib for pediatric use from Allarity Therapeutics in 2022. This drug category shows promise in addressing pediatric bone sarcomas, supported by an exploratory biomarker for identifying potential responders to the treatment.
In conclusion, the FDA's approval marks a pivotal moment in the battle against pediatric cancer. With the green light for clinical trials of volasertib and dovitinib, new hope emerges for children and their families in their fight against this devastating disease. The journey to reshape pediatric oncology continues, and the promise of improved treatments and brighter outcomes is on the horizon.
If you or a family member would like to gather additional information about these upcoming clinical trials please feel free to get in touch with Shreya Prakash by emailing her at firstname.lastname@example.org or calling/texting 425-436-8688. Alternatively, you can complete our Patient Interest Form, and EBCI will contact you.